The company’s primary focus is breast, kidney and lung cancer. The minimally invasive technology is an alternative to surgical tumor removal and is easily performed in a relatively short outpatient procedure, guided by computerized tomography. Additionally, IceCure’s solution can help institutions free up operating rooms, while potentially preventing or reducing the risk of infectious pathogens from medical procedures. These are especially critical points during the Covid-19 pandemic.